Health Ever Bio-Tech

Executive Summary

Health Ever Bio-Tech Co., Ltd. is a Taiwan-based biopharmaceutical company specializing in the development of botanical drugs for oncology. Founded in 2020, the company leverages plant-derived compounds validated through rigorous medical research to create safe and effective therapies. Its lead candidate, MCS-8, is a prostate cancer prevention agent currently in Phase II clinical trials. The company operates as a private entity with an estimated employee range of 50-200, reflecting a growing development-stage organization. While financial details such as total raised and valuation are undisclosed, Health Ever Bio-Tech's focus on botanical drug development and prostate cancer prevention positions it in a niche with significant unmet medical need. The company's progress through Phase II trials suggests a disciplined approach to clinical development, though it remains subject to typical biotech risks including regulatory hurdles and capital requirements.

Upcoming Catalysts (preview)

• Q4 2026Phase II Interim Data Readout for MCS-840% success
• Q2 2027Strategic Partnership or Licensing Agreement30% success
• Q1 2027Regulatory Milestone (e.g., IND Filing for Second Indication)25% success